MetaStat Stock

MetaStat FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of MetaStat (MTST) as of Sep 5, 2026 is 83.80 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 37.44 % — a change of 123.82% (higher).

FCF Conversion

83.80 %

YoY

123.82%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of MetaStat is 2026 83.80 % . FCF Conversion Rate (FCF/EBITDA) of MetaStat was 2025 37.44 % . It decreases by 123.82% higher compared to the previous year.

The MetaStat FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
44.21 USD
Jan 1, 2015
44.32 USD
Jan 1, 2016
54.98 USD
Jan 1, 2017
37.44 USD
Jan 1, 2018
83.80 USD
The MetaStat FCF Conversion history
YEARFCF ConversionYoY
83.80 %+123.82%
37.44 %-31.89%
54.98 %+24.05%
44.32 %+0.23%
44.21 %
Access this data via the Eulerpool API

MetaStat Stock analysis

What does MetaStat do? MetaStat Inc. is a biopharmaceutical company focused on the development of therapeutics for cancer. It was founded in Massachusetts in 2000 and has been listed on NASDAQ since 2013. The company's main focus is on blocking the protein Meta-1, which is associated with the formation of metastases, in order to stop the spread of cancer. MetaStat's business model is based on marketing medications and diagnostics. They work closely with researchers and clinicians to develop new products and conduct clinical trials. The company operates in two divisions: therapeutics and diagnostics. The therapeutics division focuses on developing medications targeting the Meta-1 protein, while the diagnostics division develops tests to detect Meta-1 protein in patients' blood to identify metastases early on. MetaStat's main product is the MetaSite Breast Test, a diagnostic test for breast cancer that uses proprietary technologies to detect the presence of Meta-1 in tumor tissue. The company also has several therapeutics in the pipeline, with MSC-1, a small molecule that blocks the function of Meta-1 and inhibits the formation of metastases, being the leading product. MetaStat has established partnerships with several research institutions and companies to advance its research and development. In summary, MetaStat is a biopharmaceutical company specializing in the development of therapeutics and diagnostics for cancer. They have developed innovative technology to detect the presence of Meta-1 in tumor tissue and inhibit the formation of metastases. Their main product is the MetaSite Breast Test, which determines the risk of metastases in breast cancer patients. The company has established partnerships with research institutions and companies to advance its research and development and further develop its pipeline of therapeutics. MetaStat is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaStat stock

FCF Conversion Rate (FCF/EBITDA) of MetaStat is 83.80 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of MetaStat changed from 37.44 % to 83.80 %, representing a 123.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) MetaStat since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s MetaStat with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — MetaStat

All Key Metrics — MetaStat